Collegium Pharmaceutical (COLL) Receivables (2016 - 2026)

Collegium Pharmaceutical has reported Receivables for 11 years, with the latest figure at $305.0 million in Q2 2026.

• On a quarterly basis, Receivables rose 43.15% year-over-year to $305.0 million in Q2 2026; TTM through Jun 2026 was $305.0 million, a 43.15% increase from a year earlier, with the FY2025 full-year figure at $231.2 million, down 8.82% from the prior year.
• Receivables was $305.0 million for Q2 2026 at Collegium Pharmaceutical, up from $248.6 million in the prior quarter.
• The five-year high for Receivables was $305.0 million in Q2 2026, with the low at $166.3 million in Q1 2022.
• Average Receivables over 5 years is $208.4 million, with a median of $196.5 million recorded in 2022.
• The sharpest annual moves came in 2022 and 2023: Receivables soared 119.21% in 2022, then decreased 15.2% in 2023.
• Over 5 years, Receivables stood at $183.1 million in 2022, then fell by 1.96% to $179.5 million in 2023, then soared by 41.23% to $253.5 million in 2024, then retreated by 8.82% to $231.2 million in 2025, then soared by 31.91% to $305.0 million in 2026.
• The last three Receivables figures came in at $305.0 million (Q2 2026), $248.6 million (Q1 2026), and $231.2 million (Q4 2025), per Business Quant data.